The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Zevra Therapeutics Inc (NASDAQ: ZVRA) closed at $11.58 down -1.28% from its previous closing price of $11.73. In other words, the price has decreased by -$1.28 from its previous closing price. On the day, 0.72 million shares were traded. ZVRA stock price reached its highest trading level at $11.826 during the session, while it also had its lowest trading level at $11.49.
Ratios:
For a deeper understanding of Zevra Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 3.02. In the meantime, Its Debt-to-Equity ratio is 1.51 whereas as Long-Term Debt/Eq ratio is at 1.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 02, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.Guggenheim initiated its Buy rating on October 07, 2024, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 26 ’25 when Thompson Rahsaan sold 24,000 shares for $9.21 per share. The transaction valued at 221,004 led to the insider holds 42,666 shares of the business.
RAHSAAN THOMPSON bought 24,000 shares of ZVRA for $223,920 on Jun 26 ’25. On Mar 28 ’25, another insider, Watton Corey Michael, who serves as the Director of the company, bought 300 shares for $7.84 each. As a result, the insider paid 2,352 and bolstered with 1,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 633189760 and an Enterprise Value of 480933632. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.60 while its Price-to-Book (P/B) ratio in mrq is 15.43. Its current Enterprise Value per Revenue stands at 11.849 whereas that against EBITDA is -7.353.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.86, which has changed by 0.8557693 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $13.16, while it has fallen to a 52-week low of $5.45. The 50-Day Moving Average of the stock is 20.48%, while the 200-Day Moving Average is calculated to be 36.85%.
Shares Statistics:
For the past three months, ZVRA has traded an average of 821.56K shares per day and 1445600 over the past ten days. A total of 54.68M shares are outstanding, with a floating share count of 54.03M. Insiders hold about 1.18% of the company’s shares, while institutions hold 65.31% stake in the company. Shares short for ZVRA as of 1749772800 were 4711373 with a Short Ratio of 6.08, compared to 1747267200 on 6009168. Therefore, it implies a Short% of Shares Outstanding of 4711373 and a Short% of Float of 8.67.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Zevra Therapeutics Inc (ZVRA) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.04 and low estimates of -$0.1.
Analysts are recommending an EPS of between $2.42 and -$0.34 for the fiscal current year, implying an average EPS of $1.21. EPS for the following year is $0.62, with 8.0 analysts recommending between $1.93 and -$0.01.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $22.46M this quarter.It ranges from a high estimate of $24.3M to a low estimate of $20.6M. As of the current estimate, Zevra Therapeutics Inc’s year-ago sales were $4.45MFor the next quarter, 8 analysts are estimating revenue of $24.29M. There is a high estimate of $26.1M for the next quarter, whereas the lowest estimate is $22.2M.
A total of 8 analysts have provided revenue estimates for ZVRA’s current fiscal year. The highest revenue estimate was $99.4M, while the lowest revenue estimate was $87M, resulting in an average revenue estimate of $93.29M. In the same quarter a year ago, actual revenue was $23.61MBased on 8 analysts’ estimates, the company’s revenue will be $162.23M in the next fiscal year. The high estimate is $232M and the low estimate is $114.6M.
